Lv1
18 积分 2026-06-26 加入
A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair-Proficient Colorectal or Pancreatic Cancer
13小时前
已完结
COMMIT: A Randomized Study of mFOLFOX6/Bevacizumab/Atezolizumab or Atezolizumab Alone as First-Line Treatment of Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
13小时前
已完结
Cuproptosis-immunity crosstalk informs strategy to sensitize cancer cells to immunotherapy
2个月前
已完结
Efficacy and safety of traditional Chinese medicine and SGLT2i, GLP‐1RA, and ACEI/ARB in the management of diabetic kidney disease: A systematic review and network meta‐analysis
2个月前
已完结
Behavioral Intervention with Eye-Use Monitoring to Delay Myopia Onset and Progression in Children
3个月前
已完结
Cuproptosis at the Crossroads of Tumor Microenvironment Inflammation and Metabolic Rewiring Mechanisms and Therapeutic Opportunities
3个月前
已完结
Integrated analysis and functional validation reveal KCNQ1 tumor suppressor targeting by dahuang Zhechong Pills via cuproptosis modulation in colorectal cancer
3个月前
已完结
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 Study
3个月前
已完结
The Randomized Phase II ARC-9 Study of Etrumadenant-Based Therapy versus Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
3个月前
已完结
皖公网安备34019202002308
